The allen institute for brain science is a 501 (c) (3) nonprofit medical research organization based in seattle, washington
GENE ACTIVITY IN THE BRAIN DEPENDS ON GENETIC BACKGROUND New Study by the Allen Institute for Brain Science Has Implications for Individual Differences in Drug Safety and Efficacy SEATTLE, Wash.—October 18, 2010—Researchers at the Allen Institute for Brain Science have found that the same genes have different activity patterns in the brain in individuals with different genetic backgrounds. These findings may help to explain individual differences in the effectiveness and side-effect profiles of therapeutic drugs and thus have implications for personalized medicine. The study is available in this week’s online early edition of the Proceedings of the National Academy of Sciences In this study, the authors compared where in the brain each of 49 different pharmaceutically related genes is expressed, or turned on, in seven genetically distinct groups of mice with known genealogical relationships. By analyzing 203 distinct brain areas over 15,000 thin sections of tissue, they precisely mapped where these genes are active, down to the level of individual cells. The genes all encode molecular targets of well-known pharmaceuticals, such as antidepressants, antipsychotics and pain relievers including Prozac, Imitrex, and Aricept. More than half of the genes examined showed striking, localized differences in expression patterns between the different genetic groups, or strains, of mice. For example, the dopamine D2 receptor gene—which encodes a target of action of Zyprexa, a drug used for schizophrenia and bipolar disorder—is active in a memory-related area called the entorhinal cortex in one strain of mice, but not in two others. Because different parts of the brain have different functions, variations in the localization of gene activity likely have functional implications. “It is clear that to understand how genes translate to behavioral and other differences between individuals and species, we need to look beyond just the inherited sequences of the genes themselves,” said Allan Jones, chief executive officer of the Allen Institute for Brain Science. “Our results show that genetic background—the specific blend of gene variants comprising an individual genome—can influence how the activity of a given gene is regulated and where it is expressed.” Taken all together, the data from the study demonstrate that closer genetic relatives exhibit fewer differences in gene expression patterns, whereas more distant relatives show greater variation. Interestingly, the researchers found that the expression variations between genetic strains were more likely to be found in areas of the brain that evolved more recently. These regions are most commonly linked to higher order functions such as cognition, social behavior, learning and memory. “This study shows how large-scale datasets can be used to reveal fundamental biological patterns that would likely be missed otherwise,” said Jones. “It is likely that many important differences between individuals and species may result from combinations of many small but clear differences in gene expression.” Jones added, “Our ongoing Allen Human Brain Atlas project, which will provide gene expression data across the brains of multiple donors, will help researchers translate these results from an animal model to a human system.” The data in this study are openly available to the public as the Mouse Diversity Study via the ALLEN Brain Atlas data portal ator directly at
Citation: JA Morris et alPNAS, published online October 18, 2010, doi: 10.1073/pnas.1003732107 About the Allen Institute for Brain Science Launched in 2003, the Seattle-based Allen Institute for Brain Science is an independent, 501(c)(3) nonprofit medical research organization dedicated to advancing brain research. Started with $100 million in seed money from philanthropist Paul G. Allen, the Institute takes on projects at the leading edge of science—far-reaching projects at the intersection of biology and technology. The resulting data create publicly available resources that fuel discovery for countless other researchers worldwide. The Institute’s data and tools are available on the Web at Media Contact: Aaron Blank, for the Allen Institute for Brain Science (206) 343-1543, (425) 736-5456 (mobile),
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases Richard K. Burt, MD Context Stem cell therapy is rapidly developing and has generated excitement and promise as well as confusion and at times contradictory results in the lay and scientific literature. Many types of stem cells show great promise, but clinical application has lagged due toethical
ª 2010 Adis Data Information BV. All rights reserved. Vanessa Cohen-Mun˜oz,1,2 Marlene Llo´piz-Avile´s,1,3 Fabia´n Llorens,4 Miguel Peniche5 and Julieta Vargas61 AMEIFAC, Mexico City, Mexico2 GlaxoSmithKline, Mexico City, Mexico3 Venn Life Sciences Ltd, Mexico City, Mexico4 Valeant Pharmaceuticals, Mexico City, Mexico5 Laboratorio Silane´s, Mexico City, Mexico6 Laboratorios Roche, Mexico C